Skip to main content
OpenTrials

Clinical trial condition

Thyroid Cancer, Papillary

Explore clinical trials studying Thyroid Cancer, Papillary. Study availability and eligibility vary by location and protocol.

139 public trials 26 recruiting studies
Refine in advanced search Browse all conditions

Thyroid Cancer, Papillary trial results

Completed

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

NCT03037385

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Diseases, +55 more
Locations
  • Mayo Clinic Hospital Phoenix, Arizona, United States
  • UC Irvine Medical Center Orange, California, United States
  • University of Colorado Anschutz Medical Campus Aurora, Colorado, United States
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
View all 71 locations
View Trial Details
Completed

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

NCT00381641

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +37 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Decatur Memorial Hospital Decatur, Illinois, United States
  • NorthShore University HealthSystem-Evanston Hospital Evanston, Illinois, United States
  • Ingalls Memorial Hospital Harvey, Illinois, United States
View all 17 locations
View Trial Details
Completed

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

NCT04731467

Conditions
Adenocarcinoma, Adenocarcinoma, Papillary, Adnexal Diseases, +48 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • University of Colorado Aurora, Colorado, United States
  • Yale University New Haven, Connecticut, United States
  • Barbara Ann Karmanos Cancer Institute Detroit, Michigan, United States
View all 18 locations
View Trial Details
Completed

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

NCT02393690

Conditions
Adenocarcinoma, Adenocarcinoma, Follicular, Adenocarcinoma, Papillary, +22 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Hoag Memorial Hospital Newport Beach, California, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View Trial Details

Related conditions